What Are the Treatment Options for Portal Hypertension?

Portal hypertension—the abnormal elevation of pressure within the portal venous system—is a serious complication most commonly associated with cirrhosis, but it can also arise from non-cirrhotic conditions such as portal vein thrombosis, schistosomiasis, or idiopathic portal hypertension. Effective management aims not only to reduce portal pressure but also to prevent life-threatening complications, including variceal bleeding, ascites, hepatic encephalopathy, and hepatorenal syndrome.

First-line pharmacologic therapy centers on non-selective beta-blockers (NSBBs), such as propranolol or carvedilol. These agents lower portal pressure by reducing cardiac output and inducing splanchnic vasoconstriction. Carvedilol offers additional alpha-1 adrenergic blockade, which may confer superior hemodynamic effects in some patients. NSBBs are indicated for both primary prophylaxis (in patients with medium-to-large esophageal varices) and secondary prophylaxis (following an episode of variceal hemorrhage).

Endoscopic interventions play a critical role in managing gastroesophageal varices. Endoscopic variceal ligation (EVL) is the preferred method for both primary and secondary prevention of variceal bleeding. It involves placing elastic bands around varices to induce thrombosis and fibrosis. For acute variceal hemorrhage, EVL is typically performed within 12–24 hours of admission, often alongside intravenous octreotide or terlipressin to reduce splanchnic blood flow and portal pressure.

In patients with refractory ascites or recurrent variceal bleeding despite optimal medical and endoscopic therapy, transjugular intrahepatic portosystemic shunt (TIPS) may be considered. TIPS creates a low-resistance channel between the hepatic vein and portal vein using an expandable metallic stent, thereby decompressing the portal system. While highly effective at controlling bleeding and ascites, TIPS carries risks—including hepatic encephalopathy and shunt dysfunction—and requires careful patient selection and lifelong surveillance.

For select patients with advanced liver disease and suitable anatomy, surgical shunts—such as mesocaval or portocaval shunts—remain an option, though they are rarely performed today due to higher perioperative morbidity and mortality compared with TIPS. Liver transplantation represents the definitive treatment for eligible patients with decompensated cirrhosis and portal hypertension, as it addresses both the underlying liver dysfunction and the hemodynamic abnormalities driving portal hypertension.

Emerging therapies under investigation include rifaximin (for its potential portal pressure–modulating and anti-inflammatory effects), statins (which may improve endothelial function and reduce intrahepatic resistance), and novel agents targeting the renin-angiotensin-aldosterone system. However, these remain adjunctive or investigational and are not yet standard of care.